Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
In this real-world study, Osimertinib achieved a significantly longer ToT compared to Afatinib in NSCLC patients with EGFR 19del and no brain metastases. The sequential use of Afatinib followed by Osimertinib showed a trend toward improved OS, highlighting the importance of rebiopsy for identifying T790M mutations to guide subsequent therapy.
Authors
- Yu‐Feng Wei (ORCID: https://orcid.org/0000-0002-6380-3527)
- Chung‐Yu Chen (ORCID: https://orcid.org/0000-0001-9002-7255)
- Jerry Shu-Hung Kuo (ORCID: https://orcid.org/0000-0002-3085-1098)
- Shih-Chieh Chang (ORCID: https://orcid.org/0009-0006-4470-1783)
- Cheng-Yu Chang
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- National Yang Ming University Hospital (TW)
- Far Eastern Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- National Yunlin University of Science and Technology (TW)
- Cardinal Tien College of Healthcare and Management (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3390/curroncol32010036
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Taiwan University Hospital
- National Taiwan University
- National Taiwan University Hospital Yunlin Branch